You may have noticed that an older dog seems to sleep all day or rarely move and when he does get up and do any type of activity, he has trouble breathing. That's because dogs, like humans, develop heart disease as they age.  One of the consequenses of heart disease is Pulmonary Hypertension (PH),  which is abnormally high blood pressure in the lungs.  This is a life threatening disease that shortens their life-span and reduces their quality of life.  Symptoms may include loss of energy, trouble breathing, dizziness during exercise and congestive heart failure.  Of the 78 million dogs in the U.S., there are approximately 8 million that suffer from PH and that number is expected to increase due to an aging American dog population.

VETNOx has developed PAPiSOL, a multi-use drug platform that has the potential to provide a complete treatment regimen for PH that will help our dogs live longer and more active lives.  PAPiSOL's unique chemistry lowers the blood pressure  in the lungs below dangerous levels without affecting the rest of the body.  It can be easily administered by a Veterinarian as well as the pet owner at home and has no known side effects.  PAPiSOL can be used to treat PH related conditions/diseases in a wide range of species.

VETNOx has developed PAPiSOL, a comprehensive treatment platform for Pulmonary Hypertension (PH) in companion animals with an initial focus on the canine. Pulmonary Hypertension is the term used to describe pathologically elevated blood pressure in the lungs.

Clinical signs for mild and moderate PH include exercise intolerant or faint/collapse with exertion. Dogs with severe PH always experience clinical signs including trouble breathing, fainting with exertion, and/or right sided congestive heart failure. There is no known cure for pulmonary hypertension so the goal of treatment is to control symptoms, prolong life-span and make the pets remaining life as comfortable and active as possible.

PH in dogs is a growing problem with heart disease affecting about 10% of dogs between 5 and 8 years of age, 20 to 25% of dogs between 9 and 12 years of age, 30 to 35% of dogs over 13 years of age and about 75% over the age of 16.  The U.S. is also seeing its canine population age as 47% of all dogs are now over six years old.

PAPiSOL is a drug that has the potential to provide a complete Pulmonary Hypertension (PH) treatment regimen when used daily.  It dilates the blood vessels in the lungs which in turns reduces the pulmonary blood pressure below dangerous levels.  In emergency situations, a veterinarian can administer a fast acting intravenous dose of PAPiSOL to help stabilize the dog.  The veterinarian will then prescribe a daily oral treatment regimen, easily administered at home by the owner, for the remainder of the dogs life.  This will help the dog feel better and be more active.  While there are other drugs used off label for PH, there is no treatment specifically designated to treat it.

The base compound in PAPiSOL has been widely tested for both effectiveness and safety in a wide variety of species. The VETNOx management team has done extensive research and development work on several other potential veterinary applications.

The VETNOx management team has worked together since 2005 when they formed ANOxA CORP, a veterinary translational and clinical research company, to commercialize their pioneering equine product EIPHiSOL. Working together they successfully developed EIPHiSOL, which is a patented treatment for Exercise Induced Pulmonary Hemorrhage (EIPH) in performance horses, from concept stage to finished product and represents a worldwide market in excess of $100 million. ANOxA holds patents in the U.S., Canada and Australia and this has led to licensing agreements to market and distribute EIPHiSOL throughout North America as well as Australia, New Zealand, Saudi Arabia, Singapore and China.

• PAPiSOL was developed as a mutli-use drug platform with applications for a wide range of species.
• VETNOx has contracted for FDA approved facilities to synthesize the raw drug product and for manufacturing of the finished product.
• We have also secured a nationwide marketing and distribution network to rapidly and efficiently facilitate market penetration. This will allow VETNOx to quickly move to a positive cash flow after product launch.
• VETNOx should become an attractive acquisition target